The Valley Desk

ArticleJournal of health economics and outcomes researchPublished

Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Journal of health economics and outcomes research
Published
Subject terms
Non-small cell lung cancer; Cost Analysis; Egfr Mutations; Adverse Event Management; Amivantamab Plus Lazertinib; Proactive Therapy Management
PubMed ID
42170243
PubMed Central ID
PMC13189261
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal